Tahseen Mozaffar, Faan

List of Publications by Year
in descending order

50 papers	1,568 citations	331670 21 h-index	330143 37 g-index
53 all docs	53 docs citations	53 times ranked	2444 citing authors

#	Article	IF	Citations
1	Homeâ€based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type <scp>R2</scp> and facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 65, 237-242.	2.2	8
2	Patient reported quality of life in limb girdle muscular dystrophy. Neuromuscular Disorders, 2022, 32, 57-64.	0.6	3
3	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Science Translational Medicine, 2022, 14, eabi9196.	12.4	27
4	A randomized <scp>placeboâ€controlled</scp> phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, 65, 291-302.	2.2	41
5	Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells. Neurology, 2022, 98, .	1.1	18
6	Utility of video-fundoscopy and prospects of portable stereo-photography of the ocular fundus in neurological patients. BMC Neurology, 2022, 22, 61.	1.8	2
7	Multisystem proteinopathy: Where myopathy and motor neuron disease converge. Muscle and Nerve, 2021, 63, 442-454.	2.2	33
8	A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. Journal of the American Academy of Dermatology, 2021, 84, 1160-1162.	1.2	10
9	Clinical utility of antiâ€cytosolic 5â€™â€nucleotidase 1A antibody in idiopathic inflammatory myopathies. Annals of Clinical and Translational Neurology, 2021, 8, 571-578.	3.7	18
10	A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression. Cell Reports, 2021, 35, 108997.	6.4	28
11	Longâ€term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Annals of Clinical and Translational Neurology, 2021, 8, 1398-1407.	3.7	22
12	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669.	2.2	11
13	IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. Journal of the Neurological Sciences, 2021, 430, 118074.	0.6	24
14	Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?. Brain, 2021, , .	7.6	0
15	COVID â€19 infection in patients with lateâ€onset Pompe disease. Muscle and Nerve, 2021, , .	2.2	2
16	Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology, The, 2021, 20, 1012-1026.	10.2	59
17	Examination of the human motor endplate after brachial plexus injury with twoâ€photon microscopy. Muscle and Nerve, 2020, 61, 390-395.	2.2	6
18	Update on immuneâ€mediated therapies for myasthenia gravis. Muscle and Nerve, 2020, 62, 579-592.	2.2	9

#	Article	IF	Citations
19	Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis. Journal of Clinical Neuromuscular Disease, 2020, 21, 246-247.	0.7	1
20	Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 263-272.	1.7	20
21	SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. Journal of Medical Genetics, 2019, 56, 693-700.	3.2	27
22	Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. Journal of Neurology, 2019, 266, 680-690.	3.6	31
23	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
24	Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. Neuroscience Letters, 2019, 699, 195-198.	2.1	8
25	QuantiMus: A Machine Learning-Based Approach for High Precision Analysis of Skeletal Muscle Morphology. Frontiers in Physiology, 2019, 10, 1416.	2.8	35
26	Oculopharyngeal Muscular Dystrophy, an Often Misdiagnosed Neuromuscular Disorder: A Southern California Experience. Journal of Clinical Neuromuscular Disease, 2019, 21, 61-68.	0.7	3
27	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve, 2019, 59, 201-207.	2.2	35
28	Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease. Annals of Translational Medicine, 2019, 7, 276-276.	1.7	13
29	Genetic landscape and novel disease mechanisms from a large <scp>LGMD</scp> cohort of 4656 patients. Annals of Clinical and Translational Neurology, 2018, 5, 1574-1587.	3.7	129
30	Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies. Current Treatment Options in Neurology, 2018, 20, 37.	1.8	2
31	A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. Neuromuscular Disorders, 2018, 28, 778-786.	0.6	7
32	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105.	1.9	68
33	Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis. Neuromuscular Disorders, 2016, 26, 741-743.	0.6	7
34	Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123.	1.1	49
35	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
36	Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity,) Tj ETQq0 0 0 rgBT /Overlock 10 2016, 26, 136-145.	0.6	31

#	Article	IF	Citations
37	Critically re-evaluating a common technique. Neurology, 2016, 86, 218-223.	1.1	29
38	GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation. Human Mutation, 2015, 36, 1159-1163.	2.5	39
39	A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa. Journal of Neuromuscular Diseases, 2015, 2, S72-S73.	2.6	1
40	Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy. Neurology: Genetics, 2015, 1, e18.	1.9	20
41	An overview of polymyositis and dermatomyositis. Muscle and Nerve, 2015, 51, 638-656.	2.2	176
42	Diagnostic value of MRI in inflammatory myositis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e128.	6.0	0
43	Desert hedgehog is a mediator of demyelination in compression neuropathies. Experimental Neurology, 2015, 271, 84-94.	4.1	17
44	A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa. Journal of Neuromuscular Diseases, 2015, 2, S72-S73.	2.6	2
45	Patient characteristics and comorbidities associated with cerebrovascular accident following acute myocardial infarction in the United States. International Journal of Cardiology, 2014, 175, 323-327.	1.7	11
46	A progressive translational mouse model of human valosinâ€containing protein disease: The VCP^{R155H/+} mouse. Muscle and Nerve, 2013, 47, 260-270.	2.2	58
47	A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Critical Reviews in Physical and Rehabilitation Medicine, 2013, 25, 11-22.	0.1	145
48	N-Glycan Processing Deficiency Promotes Spontaneous Inflammatory Demyelination and Neurodegeneration. Journal of Biological Chemistry, 2007, 282, 33725-33734.	3.4	91
49	Molecular and cellular defects of skeletal muscle in an animal model of acute quadriplegic myopathy. Muscle and Nerve, 2007, 35, 55-65.	2.2	25
50	Minocycline-induced skin and dental pigmentations. Neurology, 2006, 67, 2185-2185.	1.1	4